Codagenix develops live-attenuated viral vaccines to provide target antigens placed in an attenuated backbone virus.
Codagenix has raised $5.9M in total funding. The most recent round was Grant. The last funding was announced in October 2023.
Codagenix's investors include Serum Institute of India Pvt. Ltd., U.S. Department of War, National Institutes of Health, Adjuvant Capital, Topspin Partners.
Codagenix is headquartered in Farmingdale, United States.
Codagenix develops live-attenuated viral vaccines to provide target antigens placed in an attenuated backbone virus.
Codagenix is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Codagenix — Funding & Investors." VCBacked, October 24, 2023, https://www.vcbacked.co/company/codagenix. Accessed October 29, 2026.
VCBacked. (2023). Codagenix — Funding & Investors. Retrieved October 29, 2026, from https://www.vcbacked.co/company/codagenix
{{cite web |title=Codagenix — Funding & Investors |url=https://www.vcbacked.co/company/codagenix |website=VCBacked |access-date=October 29, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated